BFM
PLRX icon

Boothbay Fund Management’s Pliant Therapeutics PLRX Stock Holding History

Boothbay Fund Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-13,585
Closed -$396K – 2120
2021
Q2 		$396K Buy
13,585
+845
+7% +$26.3K 0.01% 1124
2021
Q1 		$501K Buy
+12,740
New +$414K 0.02% 946

Other funds holding PLRX

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Boothbay Fund Management's PLRX Position: Q3 2021 in Review

Boothbay Fund Management sold out of Pliant Therapeutics (PLRX) in Q3 2021, closing a stake of 13,585 shares — an estimated $396K sold.

Boothbay Fund Management first reported a position in PLRX in Q1 2021 and held it in 2 quarters. The position peaked at $501K in Q1 2021. 77 funds tracked by Wall St. Rank hold PLRX as of Q3 2021.

  • Boothbay Fund Management reported no remaining Pliant Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Boothbay Fund Management sold 13,585 Pliant Therapeutics shares in Q3 2021, an estimated $396K.
  • Boothbay Fund Management first reported a position in Pliant Therapeutics in Q1 2021 and held it in 2 quarters.
  • Boothbay Fund Management's Pliant Therapeutics position peaked at $501K in Q1 2021.
  • 77 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2021.

Based on Boothbay Fund Management's 13F filing for Q3 2021, filed 15 Nov 2021.